The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Mutant Selection Window Hypothesis Updated
Abstract
The mutant selection window hypothesis postulates that, for each antimicrobial-pathogen combination, an antimicrobial concentration range exists in which selective amplification of single-step, drug-resistant mutants occurs. This hypothesis suggests an antimutant dosing strategy that is keyed to the upper boundary of the selection window: the mutant prevention concentration. Correlations are described between the mutant prevention concentration--a static parameter that is measured with agar plates--and fluctuating drug concentrations that restrict mutant amplification in vitro and in animals. When drug resistance is acquired stepwise, the mutant selection window increases, making the suppression of each successive mutant increasingly more difficult. For agents that kill drug-resistant mutants in a drug concentration-dependent manner, the use of the area under the 24-h time-drug concentration curve value divided by the value of the mutant prevention concentration is suggested as an index for designing antimutant dosing regimens. The need for such regimens is emphasized by a clinical example in which acquisition of drug resistance occurs concurrently with eradication of susceptible bacterial cells. These data support using the mutant selection window to optimize antimicrobial dosing regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibacterial resistance worldwide: causes, challenges and responses
Levy, S. B., & Marshall, B. (2004) · Nature Medicine · doi:10.1038/nm1145 · Cited by 4,052
DAOUD, G. (1965) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1965.02090030355030 · Cited by 1,171
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications
Chambers, H. F. (1997) · Clinical Microbiology Reviews · doi:10.1128/cmr.10.4.781 · Cited by 1,127
Resistance to Antibiotics Mediated by Target Alterations
Spratt, B. G. (1994) · Science · doi:10.1126/science.8153626 · Cited by 674
Sieradzki, K., Roberts, R. B., Haber, S. W., & Tomasz, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400704 · Cited by 638
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. H., & Schentag, J. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.521 · Cited by 507
The mutant selection window and antimicrobial resistance
Drlica, K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg269 · Cited by 437
Self-citationZhao, X., & Drlica, K. (2001) · Clinical Infectious Diseases · doi:10.1086/321841 · Cited by 397
Self-citationResistance to ?-lactam antibiotics
Poole, K. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4060-9 · Cited by 358
Blondeau, J. M., Zhao, X., Hansen, G., & Drlica, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.433-438.2001 · Cited by 314
Self-citationVernon, A., Burman, W., Benator, D., Khan, A., & Bozeman, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11467-8 · Cited by 308
Dong, Y., Zhao, X., Domagala, J., & Drlica, K. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1756 · Cited by 278
Self-citationThe role of mutators in the emergence of antibiotic-resistant bacteria
Chopra, I., O’Neill, A. J., & Miller, K. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00041-4 · Cited by 246
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16814 · Cited by 238
The population dynamics of antimicrobial chemotherapy
Lipsitch, M., & Levin, B. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.363 · Cited by 237
Jumbe, N., Louie, A., Leary, R., Liu, W., Deziel, M. R., Tam, V. H., Bachhawat, R., Freeman, C., Kahn, J. B., Bush, K., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200316814 · Cited by 236
Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
Self-citationZhao, X., & Drlica, K. (2002) · The Journal of Infectious Diseases · doi:10.1086/338571 · Cited by 210
Self-citationPedersen, C. A. (2004) · Nature Medicine · doi:10.1038/nm0204-122 · Cited by 199
Low-level antibacterial resistance: a gateway to clinical resistance
Baquero, F. (2001) · Drug Resistance Updates · doi:10.1054/drup.2001.0196 · Cited by 193
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers
Gonzalez, M. A., Uribe, F., Moisen, S. D., Fuster, A. P., Selen, A., Welling, P. G., & Painter, B. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.5.741 · Cited by 182
Mobile Gene Cassettes and Integrons: Moving Antibiotic Resistance Genes in Gram‐Negative Bacteria
Hall, R. M. (2007) · Novartis Foundation Symposia · doi:10.1002/9780470515358.ch12 · Cited by 169
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent
Eliopoulos, G. M., Gardella, A., & Moellering, R. C. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.3.331 · Cited by 165
Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
Stratton, C. W. (2003) · Emerging infectious diseases · doi:10.3201/eid0901.020172 · Cited by 159
Blondeau, J. M., Hansen, G., Metzler, K., et al. (2004) · Journal of Chemotherapy · doi:10.1080/1120009x.2004.11782371 · Cited by 155
Zhou, J., Dong, Y., Zhao, X., Lee, S., Amin, A. G., Ramaswamy, S. V., Domagala, J. M., Musser, J. M., & Drlica, K. (2000) · The Journal of Infectious Diseases · doi:10.1086/315708 · Cited by 148
Self-citationPenicillin‐Binding Protein‐Mediated Resistance in Pneumococci and Staphylococci
Chambers, H. F. “. (1999) · The Journal of Infectious Diseases · doi:10.1086/513854 · Cited by 146
Antimicrobial Pharmacodynamics in Theory and Clinical Practice
Nightingale, & Mur (2007) · CRC Press eBooks · doi:10.3109/9781420017137 · Cited by 142
Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models
Andes, D. R., & Craig, W. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1665-1670.2002 · Cited by 140
Sieradzki, K., Łęski, T. A., Dick, J. D., Borio, L. L., & Tomasz, A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1687-1693.2003 · Cited by 135
Dong, Y., Zhao, X., Kreiswirth, B. N., & Drlica, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2581-2584.2000 · Cited by 128
Self-citationOlofsson, S. K. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl135 · Cited by 125
Pharmacodynamics of Antimicrobials: General Concepts and Applications
Craig, W. A. (2001) · doi:10.3109/9780203908372-3 · Cited by 106
Tam, V. H., Louie, A., Deziel, M. R., Liu, W., Leary, R. H., & Drusano, G. L. (2005) · The Journal of Infectious Diseases · doi:10.1086/430611 · Cited by 104
Firsov, A. A., Smirnova, M. V., Lubenko, I. Y., Vostrov, S. N., Абрамович, П. Ю., & Zinner, S. H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl387 · Cited by 100
Strategies to minimize the development of antibiotic resistance.
Baquero, F., & Negri, M. C. (1997) · PubMed · Cited by 95
Mobile Gene Cassettes: A Fundamental Resource for Bacterial Evolution
Michael, C. A., Gillings, M. R., Holmes, A. J., Hughes, L., Andrew, N. R., Holley, M. P., & Stokes, H. W. (2004) · The American Naturalist · doi:10.1086/421733 · Cited by 94
Marcusson, L. L., Olofsson, S. K., Lindgren, P. K., Cars, O., & Hughes, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki136 · Cited by 85
Effect of Rifampin on Nasal Carriage of Staphylococcus aureus
Sande, M. A., & Mandell, G. L. (1975) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.7.3.294 · Cited by 78
Mechanisms Responsible for Cross-Resistance and Dichotomous Resistance among the Quinolones
Sanders, C. C. (2001) · Clinical Infectious Diseases · doi:10.1086/319369 · Cited by 77
Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments
Campion, J. J., McNamara, P. J., & Evans, M. E. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4733-4744.2004 · Cited by 74
Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa
Hansen, G. T., Zhao, X., Drlica, K., et al. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.10.005 · Cited by 66
Self-citationCroisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H., & Chavanet, P. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh393 · Cited by 49
Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B. N., & Drlica, K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1023-1027.2003 · Cited by 46
Self-citationEtienne, M., Croisier, D., Charles, P., Lequeu, C., Piroth, L., Portier, H., Drlica, K., & Chavanet, P. (2004) · The Journal of Infectious Diseases · doi:10.1086/423853 · Cited by 42
Self-citationLi, X., Mariano, N., Rahal, J. J., Urban, C. M., & Drlica, K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4460-4462.2004 · Cited by 41
Self-citationThe in vitro activity of BMS-284756, a new des-fluorinated quinolone
Weller, T. M. A. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.1.177 · Cited by 34
Jones, R. N., Pfaller, M. A., & Stilwell, M. G. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(00)00233-9 · Cited by 29
An Anti-mutant Approach for Antimicrobial Use
Drlica, K., Wang, J.-Y., Malik, M., Lu, T., Park, S., Li, X., Perlin, D. S., & Zhao, X. (2007) · Springer eBooks · doi:10.1007/978-0-387-72418-8_11 · Cited by 5
Self-citation
Cited by
Microbiological effects of sublethal levels of antibiotics
Andersson, D. I., & Hughes, D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3270 · Cited by 1,757
Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat
Strahilevitz, J., Jacoby, G. A., Hooper, D. C., & Robicsek, A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-09 · Cited by 928
Imamovic, L., & Sommer, M. O. A. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006609 · Cited by 444
Persistence of antibiotic resistance in bacterial populations
Andersson, D. I., & Hughes, D. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00289.x · Cited by 435
Prediction of antibiotic resistance by gene expression profiles
Suzuki, S., Horinouchi, T., & Furusawa, C. (2014) · Nature Communications · doi:10.1038/ncomms6792 · Cited by 267
Metadata
- Authors
- Drlica, K., & Zhao, X.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 44
- Issue
- 5
- Pages
- 681-688
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2167806904
- Cited by
- 383
- References
- 51
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.